Nanotechnology describes the science, engineering and technology that is conducted at the nanoscale that deals with particle dimensions of less than 100 nanometres. This is functional systems at the molecular scale.
The design, characterization, production, and application of structures, devices, and systems by controlled manipulation of size and shape at the nanometer scale (atomic, molecular, and macromolecular scale) that produces structures, devices, and systems with at least one novel/superior characteristic or property.
The application of nanotechnology in medicine offers exciting possibilities from its application to drug delivery...to therapy techniques...to diagnostic techniques...to anti–microbial techniques...to cell repair.
Utilising small particle size technology such as nanoparticles can further enhance the medical delivery and hence efficacy of pharmaceutical, nutraceutical and herbal medicines such as cannabis.
Source: Adapted and modified from CA CANCER J CLIN 2013;63:395–418
Research in the nanotechnology space is to further characterise important submicron particle features that may value add to Medlab's patented technology by enhancing the science and hence efficacy of medicinal compounds such as Vitamin D3, Ascorbate, Vitamin B12,and whole plant extract cannabis.
Beyond the Cannabis application, Medlab sees a real benefit in repurposing many generic pharmaceuticals with a lower dosage format and reduction in reported side effects. Medlab's pharmaceutical agenda has brought-about development in NanoCelle'ed Statins, Insulin, Steriods, ACEi's, Antibiotics, and immunosuppressive Agents to name a few. See Currently in Development, below.
Notwithstanding, whilst Medlab favours the buccal route, application for NanoCelle'ed API delivery is underway for nasal and topical as well.
While submicron particle suspensions have complex particle size distributions in that the particle size distribution is broad consisting of several distinct particle populations of varying sizes where most have greater than 100 nanometres particle sizes (e.g., emulsions, liposomes), Medlab's nanocelle patented technology was developed with research on submicron particles spanning more than two decades. Demonstrating critical sub micron particle size characteristics well below 100 nanometres.
Who we use and why
PTL is a premier particle technology research and advisory company. We are a trusted advisor to the world's leading pharmaceutical, industrial, public sector and scientific organizations. We work with, and provide advice to, major organizations across the private, public, and scientific research sectors. PTL is free from all commercial bias.
Particle Technology Labs currently has the capability to provide this service in-house using our NanoSight LM10-HSBT14, which is the first cGMP-certified instrument of its kind in the United States. The NanoSight LM10-HSBT14 utilizes Nanoparticle Tracking Analysis (NTA) technology, which is one of the first commercially available technologies allowing high-resolution particle size distribution on a number-weighted basis and concentration analyses of submicron particles.
NTA technology employs the following steps:
ASTM E2834-12 describes this innovative technique and provides guidance for industry use.
Another option that PTL has for the analysis of submicron particles is through Dynamic Light Scattering (DLS).
DLS is a commonly-used term to describe a technique which measures the particle size and estimated distribution of submicron particulate systems on an intensity-weighted basis. In addition, the terms Photon Correlation Spectroscopy (PCS) and Quasi-Elastic Light Scattering (QELS) have also been used historically to refer to the same analytical principle. By any name, the technique is widely recognized throughout the pharmaceutical and industrial world reflected in the existence of several standards describing the technique (i.e. ISO 22412, ISO 13321, and ASTM E2490-09).
DLS requires particles approximately less than a micron in size to be homogenously suspended in a fluid (aqueous or organic). A few examples of suitable systems could include:
DLS technlogy employs the following steps:
In simple terms, small particles move/diffuse more rapidly than larger particles.
While other reporting formats are available, the most widely accepted and recommended way to report results from DLS is on an intensity basis using the Z-Average along with the Polydispersity Index (PDI). The PDI is an indicator of the “broadness” of the particle size distribution. DLS technology also allows for the determination of the critical micelle concentration (CMC) for various surfactants. In addition, a DLS instrument at PTL is capable of determining zeta potential in an aqueous suspension as well as isoelectric point determination (IEP).
Comparative blood work
HREC Number: 003/032014
14% of tablet is active, side effects - opportunity to improve
|Atorvastatin in water (1.7 mg/mL) and Nanocelled Atorvastatin (1.7 mg/mL)||Rosuvastatin in water ( 5 mg/mL) and Nanocelled Rosuvastatin ( 10mg /mL)|
Table of particle sized API's
|Particle||Particle Size (nm)||Concentration|
|Ampicillin Sodium Salt (2162016AMP)-antibiotics||12.85||2 mg/mL|
|Atorvasatatin (1022015ATO)||11.41||10 mg/mL|
|Atorvastatin (1232015ATO)||89.31||0.1 mg/mL|
|Atorvastatin-25 (12142015ATO25)||14.62||1.67 mg/mL|
|Atorvastatin-30 (12142015ATO30)||14.37||1.67 mg/mL|
|Atorvastation (2162016ATO)||12.71||10 mg/mL|
|Beta-Estradiol (2162016EST)-hormones||16.43||1 mg/mL|
|Insulin (1022015INS)||3.843||15 IU/mL|
|Perindopril Erbumine (2162016PER)-ACEi||12.7||7 mg/mL|
|Progestogen (2162016PRO)-hormones||15.48||2 mg/mL|
|Rosuvastatin (1022015ROS)-statin||12.19||2 mg/mL|
|Sertraline Hydrochloride (2162016SER)-SSRI||15.21||0.5 mg/mL|
|Testosterone Propionate (1232015TES)-hormones||14.31||15 mg/mL|
|D3||31.01||1000 IU/0.3 mL|
|D3 & K2 (2182016D3K2)||28||1000 IU+ 45 mg/0.3 mL|
|Melatonin (2182016MEL)||23||2.5 mg/0.3 mL|
|Cyanocobalamin B12||24.8||1000mg/0.3 mL|
|Methlycobalamin B12 (2182016B12)||18.9||1000mg/0.3 mL|